Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 5.7%

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) traded down 5.7% during trading on Tuesday . The company traded as low as $23.84 and last traded at $24.02. 19,712 shares were traded during mid-day trading, a decline of 86% from the average session volume of 138,474 shares. The stock had previously closed at $25.46.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Jefferies Financial Group increased their target price on Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Wedbush upped their price target on Dianthus Therapeutics from $33.00 to $38.00 and gave the company an “outperform” rating in a report on Friday, May 10th. Stifel Nicolaus initiated coverage on Dianthus Therapeutics in a report on Thursday, February 15th. They set a “buy” rating and a $44.00 price target on the stock. Raymond James upped their price target on Dianthus Therapeutics from $34.00 to $51.00 and gave the company an “outperform” rating in a report on Thursday, April 18th. Finally, HC Wainwright initiated coverage on Dianthus Therapeutics in a report on Thursday, May 16th. They set a “buy” rating and a $40.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $42.83.

Dianthus Therapeutics Stock Down 5.6 %

The firm has a 50 day moving average price of $25.50 and a 200 day moving average price of $19.18. The stock has a market cap of $638.95 million, a P/E ratio of -3.73 and a beta of 1.77.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($1.11) by $0.40. The company had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.73 million. Equities analysts predict that Dianthus Therapeutics, Inc. will post -2.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC purchased a new stake in shares of Dianthus Therapeutics during the 4th quarter worth approximately $25,000. Citigroup Inc. purchased a new stake in Dianthus Therapeutics during the 3rd quarter valued at $53,000. Virtu Financial LLC purchased a new stake in Dianthus Therapeutics during the 1st quarter valued at $390,000. Hussman Strategic Advisors Inc. purchased a new stake in Dianthus Therapeutics during the 1st quarter valued at $630,000. Finally, Acadian Asset Management LLC purchased a new stake in Dianthus Therapeutics during the 3rd quarter valued at $303,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.